Financhill
Buy
59

ADUS Quote, Financials, Valuation and Earnings

Last price:
$131.23
Seasonality move :
3.51%
Day range:
$126.14 - $132.55
52-week range:
$85.94 - $136.12
Dividend yield:
0%
P/E ratio:
30.07x
P/S ratio:
1.95x
P/B ratio:
2.51x
Volume:
458.8K
Avg. volume:
152.3K
1-year change:
38.81%
Market cap:
$2.4B
Revenue:
$1.1B
EPS (TTM):
$4.37

Analysts' Opinion

  • Consensus Rating
    Addus HomeCare has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $137.82, Addus HomeCare has an estimated upside of 4.89% from its current price of $131.40.
  • Price Target Downside
    According to analysts, the lowest downside price target is $83.00 representing 36.83% downside risk from its current price of $131.40.

Fair Value

  • According to the consensus of 8 analysts, Addus HomeCare has 4.89% upside to fair value with a price target of $137.82 per share.

ADUS vs. S&P 500

  • Over the past 5 trading days, Addus HomeCare has overperformed the S&P 500 by 7.25% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Addus HomeCare does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Addus HomeCare has grown year-over-year revenues for 48 quarters straight. In the most recent quarter Addus HomeCare reported revenues of $289.8M.

Earnings Growth

  • Addus HomeCare has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Addus HomeCare reported earnings per share of $1.10.
Enterprise value:
2.2B
EV / Invested capital:
2.28x
Price / LTM sales:
1.95x
EV / EBIT:
20.18x
EV / Revenue:
1.90x
PEG ratio (5yr expected):
1.30x
EV / Free cash flow:
17.09x
Price / Operating cash flow:
17.53x
Enterprise value / EBITDA:
17.84x
Gross Profit (TTM):
$366M
Return On Assets:
6.89%
Net Income Margin (TTM):
6.5%
Return On Equity:
9.24%
Return On Invested Capital:
8.42%
Operating Margin:
8.96%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $928.7M $1B $1.1B $270.7M $289.8M
Gross Profit $293.8M $326.2M $366M $86.7M $92.2M
Operating Income $67.3M $83.8M $103.7M $22.8M $26M
EBITDA $82.2M $98.8M $121M $27M $31.3M
Diluted EPS $2.75 $3.55 $4.37 $0.95 $1.10
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $299.4M $299.7M $240.1M $211.2M $332.8M
Total Assets $695.4M $924.9M $945.9M $1B $1.2B
Current Liabilities $93.7M $112.5M $128.2M $139.6M $157.8M
Total Liabilities $187.8M $366.9M $331.1M $351.4M $205.3M
Total Equity $507.6M $558.1M $614.8M $684.3M $947.6M
Total Debt $61.7M $220.7M $163.6M $163.9M --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $106M $106.5M $136.1M $21.8M $48.5M
Cash From Investing -$96.9M -$133.2M -$5.4M -$111.2M -$1.9M
Cash From Financing -$55.8M $786K $12.5M $85M $2.9M
Free Cash Flow $101.7M $96.9M $126.4M $19.4M $46.6M
ADUS
Sector
Market Cap
$2.4B
$44.6M
Price % of 52-Week High
96.53%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
38.81%
-29.09%
Beta (5-Year)
1.015
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $127.48
200-day SMA
Buy
Level $118.14
Bollinger Bands (100)
Buy
Level 123.23 - 131.69
Chaikin Money Flow
Buy
Level 13.1M
20-day SMA
Buy
Level $124.46
Relative Strength Index (RSI14)
Buy
Level 63.37
ADX Line
Sell
Level 7.45
Williams %R
Sell
Level -8.5028
50-day SMA
Buy
Level $125.94
MACD (12, 26)
Buy
Level 1.41
25-day Aroon Oscillator
Buy
Level 88
On Balance Volume
Neutral
Level 22M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.6545)
Buy
CA Score (Annual)
Level (1.2234)
Buy
Beneish M-Score (Annual)
Level (-2.714)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-1.3414)
Buy
Piotroski F Score (Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.

Stock Forecast FAQ

In the current month, ADUS has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADUS average analyst price target in the past 3 months is $137.82.

  • Where Will Addus HomeCare Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Addus HomeCare share price will rise to $137.82 per share over the next 12 months.

  • What Do Analysts Say About Addus HomeCare?

    Analysts are divided on their view about Addus HomeCare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Addus HomeCare is a Sell and believe this share price will drop from its current level to $83.00.

  • What Is Addus HomeCare's Price Target?

    The price target for Addus HomeCare over the next 1-year time period is forecast to be $137.82 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is ADUS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Addus HomeCare is a Buy. 8 of 8 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ADUS?

    You can purchase shares of Addus HomeCare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Addus HomeCare shares.

  • What Is The Addus HomeCare Share Price Today?

    Addus HomeCare was last trading at $131.23 per share. This represents the most recent stock quote for Addus HomeCare. Yesterday, Addus HomeCare closed at $131.40 per share.

  • How To Buy Addus HomeCare Stock Online?

    In order to purchase Addus HomeCare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock